Teva taps new North American commercial chief as key meds Ajovy, Austedo lag their rivals

Fresh off a global cost-cutting spree and with Teva's branded medicines lagging against their rivals, CEO Kåre Schultz is again changing his executive ranks.

Brendan O’Grady, who Schultz previously tapped to lead Teva’s North American commercial business, is leaving the company to pursue other opportunities, the company said. Teva’s executive vice president of marketing and portfolio in international markets, Sven Dethlefs, is taking the post.